Angioimmunoblastic T-cell lymphoma

Related records

Broader conditions (18)

• Cancer or benign tumor
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Hematologic disorder
• Hematopoietic and lymphoid cell neoplasm
• Hematopoietic and lymphoid system neoplasm
• Human disease
• Lymphoid hemopathy
• Lymphoid neoplasm
• Lymphoma
• Mature T-cell and NK-cell non-Hodgkin lymphoma
• Neoplasm
• Neoplasm of mature T-cells or NK-cells
• Neoplastic disease or syndrome
• Non-Hodgkin lymphoma
• T-cell and NK-cell neoplasm
• T-cell non-Hodgkin lymphoma

Trials (276)

• 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
• 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
• 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
• 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
• 506U78 in Treating Patients With Lymphoma
• 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
• A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
• A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
• A Registry for People With T-cell Lymphoma
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
• A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
• A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
• A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
• Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
• Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

Drugs in development (25)

• Alemtuzumab Phase 3
• Azacitidine Phase 3
• Bendamustine Phase 3
• Cisplatin Phase 2
• Cyclophosphamide Phase 3
• Dasatinib anhydrous Phase 1
• Doxorubicin Phase 3
• Fludarabine phosphate Phase 2
• Gemcitabine Phase 3
• Irinotecan hydrochloride Phase 1
• Melphalan Phase 2
• Methotrexate Phase 2
• Methylprednisolone Phase 2
• Mitoxantrone Phase 1
• Mycophenolate mofetil Phase 2
• Plitidepsin Phase 2
• Prednisolone Phase 2
• Prednisone Phase 2
• Rituximab Phase 2
• Romidepsin Phase 3